By Annette von Delft, Translational Scientist, Centre for Medicines Discovery, University of Oxford, Charles Mowbray, Discovery Director, DNDi, Borna Nyaoke, Senior Clinical Project Manager, DNDi

Antiviral pills to treat SARS-CoV-2 infection are finally starting to arrive. This week’s announcement of the US Food and Drug Administration’s approval of the first two oral antivirals for COVID-19, including Merck’s molnupiravir, and Pfizer’s Paxlovid™, has stirred much attention for the potential of the new treatments to significantly reduce risks of serious COVID disease through therapies available at point-of-care.  

Read the viewpoint published in Health Policy Watch (no paywall)